%0 Journal Article %A Faiza Gaba %A Nicolò Bizzarri %A Paul Kamfwa %A Allison Saiz %A Oleg Blyuss %A Shantini Paranjothy %A Pedro T Ramirez %A David Cibula %A , %T Determining post-operative morbidity and mortality following gynecological oncology surgery: protocol for a multicenter, international, prospective cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative—GO SOAR) %D 2021 %R 10.1136/ijgc-2021-002586 %J International Journal of Gynecologic Cancer %P 1287-1291 %V 31 %N 9 %X Background The Global Gynaecological Oncology Surgical Outcomes Collaborative (GO SOAR) aims to develop a network of gynecological oncology surgeons, surgical departments, and other interested parties that will have the long-term ability to collaborate on outcome studies. The protocol for the first collaborative study is presented here.Primary Objective To evaluate international variation in 30-day post-operative morbidity and mortality following gynecological oncology surgery between very high/high and medium/low human development index country settings.Hypothesis There is no variation in post-operative morbidity and mortality following gynecological oncology surgery between very high/high and medium/low human development index country settings.Study Design International, multicenter, prospective cohort study. Patient data will be collected over a consecutive 30-day period through gynecological oncology multidisciplinary teams/tumor boards and clinics across different human development index country groups. All data are collected on a customized, secure, password protected, central REDCap database.Major Inclusion/Exclusion Criteria Inclusion criteria include women aged ≥18 years undergoing elective/emergency, curative/palliative surgery for primary/recurrent tubo-ovarian/peritoneal, endometrial, cervical, vulval, vaginal, gestational trophoblastic malignancies. Surgical modality may be open, minimal access (laparoscopic/robotic), or vaginal.Primary Endpoint 30-day post-operative morbidity and mortality defined as per Clavien-Dindo classification system.Sample Size 1100 (550/arm).Estimated Dates for Completing Accrual and Presenting Results It is estimated recruitment will be completed by 2022 and results published by 2023.Trial Registration ClinicalTrials.gov registry: NCT04579861 (https://clinicaltrials.gov/ct2/show/NCT04579861).There are no data in this work. %U https://ijgc.bmj.com/content/ijgc/31/9/1287.full.pdf